Newly diagnosed multiple myeloma trial for transplant-ineligible patients
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma and cannot have a stem cell transplant.
- Your cancer shows signs that can be measured by tests.
- Your organs and blood counts are working well enough for this treatment.
- You are not pregnant, not breastfeeding, and agree to use birth control during the study and for 5 months after the last dose.
- You do not have other blood cancers, active infections, or serious health issues that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This trial tests a combination of immunotherapy drugs for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this approach can better control the disease.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma in patients who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control myeloma and improve survival.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.